Free Trial
ASX:PME

Pro Medicus (PME) Stock Price, News & Analysis

Pro Medicus logo

About Pro Medicus Stock (ASX:PME)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
285,954 shs
Average Volume
N/A
Market Capitalization
$29.16 billion
P/E Ratio
351.99
Dividend Yield
0.14%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Pro Medicus Limited engages in the development and supply of healthcare imaging software and services to hospitals, diagnostic imaging groups, and other related health entities in Australia, North America, and Europe. The company offers Visage radiology information systems (RIS), a proprietary medical software for practice management, training, installation, professional services, and after-sale support and service products; and Promedicus.net, an e-health platform. It also provides healthcare imaging software that provides radiologists and clinicians with visualization capability for viewing 2-D, 3-D, and 4-D medical images, as well as picture archive and communication system (PACS)/digital imaging software; and integration products. In addition, the company offers Visage Ease Pro, a mobile application that provides users the ability to interpret various diagnostic imaging studies stored on a Visage 7 server. The company provides its products under the Visage RIS, Visage RIS/PACS, Visage 7, Visage Ease Pro, and Visage Ease names. Pro Medicus Limited was incorporated in 1983 and is headquartered in Richmond, Australia.

Receive PME Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pro Medicus and its competitors with MarketBeat's FREE daily newsletter.

PME Stock News Headlines

Pro Medicus shares rise on big AI news
Trump’s Secret Weapon
Have you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's coming next. But here's the truth… This is just the beginning. Trump has made it clear his tariffs are coming, and that the market will get worse before it gets better. Luckily, our FREE Presidential Transition Guide details exactly what will happen in the next 100 days, and how to protect your hard-earned savings during these times. Don't wait for the next crash to wipe you out. Act now.
Bell Potter Keeps Their Buy Rating on Pro Medicus Limited (PMCUF)
See More Headlines

PME Stock Analysis - Frequently Asked Questions

Based on aggregate information from My MarketBeat watchlists, some other companies that Pro Medicus investors own include Mineral Resources (MIN), ResMed (RMD), Technology One (TNE), ARB (ARB), Accent Group (AX1), Cochlear (COH) and CSL (CSL).

Company Calendar

Ex-Dividend for 3/20 Dividend
2/26/2025
Record date for 3/20 Dividend
3/20/2025
Dividend Payable
3/20/2025
Today
4/27/2025

Industry, Sector and Symbol

Stock Exchange
ASX
Sector
Medical
Industry
Health Information Services
Sub-Industry
N/A
Current Symbol
ASX:PME
CIK
N/A
Fax
N/A
Employees
2,060
Year Founded
N/A

Profitability

Trailing P/E Ratio
351.99
Forward P/E Ratio
N/A
P/E Growth
3.87
Net Income
$82.79 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$161.50 million
Price / Cash Flow
71.76
Book Value
A$1.80 per share
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$29.16 billion
Optionable
Not Optionable
Beta
0.56
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

This page (ASX:PME) was last updated on 4/27/2025 by MarketBeat.com Staff
From Our Partners